NCT07619573

Brief Summary

Background: Irritable Bowel Syndrome (IBS) is the most prevalent functional gastrointestinal (GI) pathology among GI disorders. Various dietary interventions, particularly the low-FODMAP diet, are employed to alleviate IBS symptoms. Study Population \& Design: This study will include 78 adult patients, aged 18-65, diagnosed with IBS according to Rome IV criteria at the Biruni University Faculty of Medicine Hospital Gastroenterology Outpatient Clinic. Participants will be divided into two parallel groups: Group 1 (n=39): Will receive dietary intervention solely through physician follow-up (provided with a standard hospital brochure listing prohibited foods). Group 2 (n=39): Will receive structured, personalized dietary intervention through individualized nutritional counseling by a dietitian. Duration: The low-FODMAP diet intervention for both groups will last for 8 weeks. Outcome Measures: At baseline (week 0) and at the conclusion of the study (week 8), the following assessments will be conducted: Clinical Scores: IBS Symptom Severity Score (IBS-SSS) and the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Biomarkers: Hs-CRP and fecal calprotectin levels analyzed from blood and stool samples. Objective: The primary objective is to determine the impact of individualized nutritional counseling on GI symptoms and inflammatory biomarkers (hs-CRP, fecal calprotectin) during a low-FODMAP diet. Secondary objectives include evaluating the significance of the dietitian's role and observing how lifestyle factors (sleep and physical activity) influence symptom outcomes alongside nutritional therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2025

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 2, 2026

Completed
Last Updated

June 2, 2026

Status Verified

May 1, 2026

Enrollment Period

6 months

First QC Date

May 26, 2026

Last Update Submit

May 26, 2026

Conditions

Keywords

Irritable Bowel Syndrome (IBS)low-FODMAP dietgastrointestinal symptomsdietitian

Outcome Measures

Primary Outcomes (4)

  • IBS-SSS

    Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS). The IBS-SSS consists of 5 questions, each scored from 0 to 100, with a maximum possible total score of 500. It determines the severity of abdominal pain, abdominal pain frequency, abdominal bloating severity, satisfaction with bowel habits, and the impact of the disease on quality of life. Total scores are classified as follows: 75-174 points = mild IBS, 175-299 points = moderate IBS, and greater than or equal to 300 points = severe IBS. Higher scores indicate more severe IBS symptoms.

    From enrollment to the end of treatment at 8 weeks

  • GSRS

    Gastrointestinal Symptom Rating Scale (GSRS). The GSRS is a 15-item questionnaire that uses a 5-point Likert scale to assess the severity of gastrointestinal symptoms across 5 subscales: abdominal pain, reflux, diarrhoea, indigestion, and constipation. Scores are aggregated to determine symptom severity, where higher scores represent a higher severity of gastrointestinal symptoms.

    From enrollment to the end of treatment at 8 weeks

  • Fecal Calprotectin

    Fecal calprotectin levels will be analyzed from stool samples collected from participants to evaluate gastrointestinal inflammation.

    From enrollment to the end of treatment at 8 weeks

  • Hs-CRP

    High-Sensitivity C-Reactive Protein (hs-CRP). Hs-CRP levels will be analyzed from blood samples collected from individuals to monitor systemic biochemical findings of inflammation.

    From enrollment to the end of treatment at 8 weeks

Secondary Outcomes (5)

  • Anthropometric measurement data

    From enrollment to the end of treatment at 8 weeks

  • IPAQ-SF

    From enrollment to the end of treatment at 8 weeks

  • Epworth Sleepiness Scale (ESS)

    From enrollment to the end of treatment at 8 weeks

  • Data Collection Form

    At the beginning of the study

  • Daily Total FODMAP Intake

    From enrollment to the end of treatment at 8 weeks

Study Arms (2)

Dietitian group

EXPERIMENTAL

A dietitian planned the low FODMAP diet for the first group (n=31) through individual dietary counselling.

Behavioral: Low-FODMAP Diet Intervention

Doctor group

ACTIVE COMPARATOR

The second group (n=19) was given a brochure on the low FODMAP diet, as is routine in the hospital, listing foods prohibited by the gastroenterologist.

Behavioral: Low-FODMAP Diet Intervention

Interventions

This intervention consists of an 8-week low-FODMAP dietary regimen aimed at restricting the intake of short-chain carbohydrates, including fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The intervention is administered through two distinct protocols to compare delivery methods: one group receives standard hospital care consisting of a brief physician follow-up accompanied by a standard educational brochure listing prohibited foods, while the other group receives structured, individualized nutritional counseling and personalized meal planning led by a professional dietitian.

Dietitian groupDoctor group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18-65 years.
  • Diagnosed with IBS according to the Rome IV criteria.

You may not qualify if:

  • Use of antibiotics, NSAIDs, oral contraceptives, or hormone therapy during the study.
  • Pregnancy or breastfeeding.
  • Diagnosis of celiac disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Biruni University Faculty of Medicine Hospital

Istanbul, Istanbul, Turkey (Türkiye)

Location

Biruni University

Istanbul, Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Sevde KAHRAMAN, Asst. Prof.

    Biruni University

    STUDY CHAIR
  • Zeynep Çavdar, Master's student and dietitan

    Biruni University

    STUDY DIRECTOR
  • Koray Koçhan, Specialist of Gastroenterology

    Department of Gastroenterology, Biruni University Faculty of Medicine Hospital

    PRINCIPAL INVESTIGATOR
  • Huri Demirci, PhD, Associate Professor

    Biruni University

    PRINCIPAL INVESTIGATOR
  • Fatma Çelik, PhD, Professor

    Biruni University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The patients were randomly assigned to two groups: One group (n=31) followed a low FODMAP diet under the guidance of a dietitian, while the other group (n=19) followed the diet based on a brochure provided by a doctor.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Asst. Prof.

Study Record Dates

First Submitted

May 26, 2026

First Posted

June 2, 2026

Study Start

April 1, 2025

Primary Completion

October 1, 2025

Study Completion

October 30, 2025

Last Updated

June 2, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations